[A20-36] Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2020
Project no.:
A20-36
Commission:
Commission awarded on 31.03.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease
Clear advantages in overall survival and symptomatic progression, disadvantages in some side effects; overall: indication of considerable added benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-20 | Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-09 | Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |